Annovis Bio, Inc.(ANVS)Earnings, Financials & Key Ratios
ANVS•NYSE
$2.27
$62M mkt cap·Price updated May 6, 2026
AboutAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Show more
- Revenue$0
- EBITDA-$30M-11.2%
- Net Income-$29M-17.3%
- EPS (Diluted)-1.40+99.9%
- ROE-0.34%+100.0%
ANVS Key Insights
Annovis Bio, Inc. (ANVS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Shares diluted 68.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ANVS Price & Volume
Annovis Bio, Inc. (ANVS) stock price & volume — 10-year historical chart
Loading chart...
ANVS Growth Metrics
Annovis Bio, Inc. (ANVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.34%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM22.61%
Return on Capital
10 Years-153.88%
5 Years-144.69%
3 Years-199.18%
Last Year-0.34%
ANVS Peer Comparison
Annovis Bio, Inc. (ANVS) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 PRTA | 602.39M | 11.19 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 ACAD | 3.78B | 22.35 | 16.43 | 31.85% | 24.94% | 28.47% | 4.16% | 0.07 |
 AVXL | 311.38M | 3.36 | -6.22 | -31.55% | ||||
 ATHA | 17.12M | 4.34 | -0.17 | -340.97% | 0.03 | |||
 BIIB | 27.92B | 189.13 | 21.42 | 1.39% | 13.92% | 7.55% | 7.34% | 0.38 |
 LLY | 933.66B | 988.19 | 43.06 | 44.7% | 34.98% | 101.17% | 0.96% | 1.60 |
 ALNY | 40.18B | 301.11 | 129.23 | 65.19% | 13.46% | 98.29% | 1.16% | 1.62 |
Compare ANVS vs Peers
Annovis Bio, Inc. (ANVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANVS Income Statement
Annovis Bio, Inc. (ANVS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 682.43K | 713.94K | 1.61M | 6.64M | 14.54M | 25.51M | 45.03M | 26.69M | 29.7M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 409.06K | 602.33K | 829.37K | 3.59M | 6.06M | 9M | 6.24M | 6.7M | 4.48B |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 273.37K | 111.61K | 776.26K | 3.05M | 8.48M | 16.52M | 38.79M | 20M | 25.22B |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 378 | 0 | 0 | 0 | 0 | 0 | -29.67B |
| Operating Income | -682K▲ 0% | -714K▼ 4.7% | -1.61M▼ 124.9% | -6.64M▼ 313.5% | -14.54M▼ 118.9% | -25.51M▼ 75.5% | -45.03M▼ 76.5% | -26.69M▲ 40.7% | -29.7M▼ 11.2% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -4.69% | -124.93% | -313.46% | -118.93% | -75.49% | -76.53% | 40.72% | -11.24% |
| EBITDA | 433 | -63 | 0 | 0 | -14.5M | -25.51M | -45.03M | -26.69M | -29.7M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -114.55% | 100% | - | - | -75.93% | -76.53% | 40.72% | -11.24% |
| D&A (Non-Cash Add-back) | 682.43K | 713.94K | 1.61M | 6.64M | 0 | 0 | 0 | 0 | 0 |
| EBIT | -682K | -714K | -1.61M | -6.64M | -14.5M | -25.51M | -45.03M | -26.69M | -29.7M |
| Net Interest Income | 0 | 0 | 0 | -47.18M | 13.34K | 182.71K | 667.9K | -1.52M | 699.06K |
| Interest Income | 0 | 0 | 0 | 47.23K | 13.34K | 182.71K | 667.9K | 331.85K | 699.06K |
| Interest Expense | 84 | 66 | 0 | 47.23M | 0 | 0 | 0 | 1.85M | 0 |
| Other Income/Expense | 84 | 66 | 614.64K | 1.18M | 50.09K | 182.71K | -11.17M | 2.1M | 841.06K |
| Pretax Income | -682K▲ 0% | -714K▼ 4.7% | -991K▼ 38.8% | -5.46M▼ 451.2% | -14.49M▼ 165.2% | -25.33M▼ 74.8% | -56.2M▼ 121.9% | -24.59M▲ 56.2% | -28.85M▼ 17.3% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | -132 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0.02% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -682K▲ 0% | -714K▼ 4.7% | -991K▼ 38.8% | -5.46M▼ 451.2% | -14.49M▼ 165.2% | -25.33M▼ 74.8% | -56.2M▼ 121.9% | -24.59M▲ 56.2% | -28.85M▼ 17.3% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -4.69% | -38.8% | -451.17% | -165.23% | -74.83% | -121.9% | 56.25% | -17.34% |
| Net Income (Continuing) | -682K | -714K | -991K | -5.46M | -14.49M | -25.33M | -56.2M | -24.59M | -28.85M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.16▲ 0% | -0.16▲ 0.0% | -0.17▼ 6.3% | -0.87▼ 411.8% | -1.90▼ 118.4% | -3.10▼ 63.2% | -6.23▼ 101.0% | -2009.77▼ 32159.6% | -1.40▲ 99.9% |
| EPS Growth % | - | 0% | -6.25% | -411.76% | -118.39% | -63.16% | -100.97% | -32159.55% | 99.93% |
| EPS (Basic) | -0.16 | -0.16 | -0.17 | -0.87 | -1.90 | -3.10 | -6.23 | -2018.50 | -1.40 |
| Diluted Shares Outstanding | 4.39M | 4.4M | 6.84M | 6.31M | 7.63M | 8.16M | 9.02M | 12.23M | 20.55M |
| Basic Shares Outstanding | 4.39M | 4.4M | 6.84M | 6.31M | 7.63M | 8.16M | 9.02M | 12.18M | 20.55M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ANVS Balance Sheet
Annovis Bio, Inc. (ANVS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 357.96K | 50.99K | 747.51K | 8.12M | 46M | 36.02M | 10.21M | 13.93M | 19.53B |
| Cash & Short-Term Investments | 347.47K | 35.31K | 1.86K | 8.07M | 45.69M | 28.38M | 5.75M | 10.55M | 19.53B |
| Cash Only | 347.47K | 35.31K | 1.86K | 8.07M | 45.69M | 28.38M | 5.75M | 10.55M | 19.53B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 735.08K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | -745.64M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 745.65M | 6.44K | 9.87K | 7.54M | 20.8K | 7.5K | 0 |
| Total Non-Current Assets | 0 | 0 | 369.6K | 0 | 0 | 0 | 0 | 0 | 1.55B |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 369.6K | 0 | 0 | 0 | 0 | 0 | 1.55B |
| Total Assets | 357.96K▲ 0% | 50.99K▼ 85.8% | 1.12M▲ 2090.7% | 8.12M▲ 626.8% | 46M▲ 466.6% | 36.02M▼ 21.7% | 10.21M▼ 71.7% | 13.93M▲ 36.4% | 21.08B▲ 151287.2% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | - | -85.76% | 2090.75% | 626.82% | 466.57% | -21.69% | -71.66% | 36.42% | 151287.19% |
| Total Current Liabilities | 490.22K | 567.94K | 2.01M | 578.38K | 1.51M | 7.7M | 4.28M | 3.88M | 3.64B |
| Accounts Payable | 71.11K | 68.42K | 1.23M | 341.86K | 688.07K | 3.96M | 1.29M | 2.31M | 2.59M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 415.35K | 477.88K | 645.34K | 220.03K | 105.67K | 0 | 273 | 1.21M | 3.63B |
| Current Ratio | 0.73x | 0.09x | 0.37x | 14.04x | 30.54x | 4.68x | 2.39x | 3.59x | 5.37x |
| Quick Ratio | 0.73x | 0.09x | 371.20x | 14.04x | 30.54x | 4.68x | 2.39x | 3.59x | 5.37x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.83M | 7.08M | 7.68M | 0 | 0 | 0 | 13.68M | 737K | 595M |
| Long-Term Debt | 0 | 0 | 499.81K | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 6.83M | 7.08M | 7.18M | 0 | 0 | 0 | 13.68M | 737K | 595M |
| Total Liabilities | 7.32M | 7.64M | 9.69M | 578.38K | 1.51M | 7.7M | 17.96M | 4.62M | 4.23B |
| Total Debt | 0 | 0 | 499.81K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -347.47K | -35.31K | 497.95K | -8.07M | -45.69M | -28.38M | -5.75M | -10.55M | -19.53B |
| Debt / Equity | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -802.48x | - | - | - | - | - | - | - | - |
| Interest Coverage | -8119.05x | -10818.18x | - | -0.14x | - | - | - | -14.40x | - |
| Total Equity | -6.97M▲ 0% | -7.59M▼ 9.0% | -8.58M▼ 12.9% | 7.54M▲ 187.9% | 44.49M▲ 490.0% | 28.32M▼ 36.3% | -7.75M▼ 127.4% | 9.31M▲ 220.1% | 16.85B▲ 180947.4% |
| Equity Growth % | - | -9.02% | -12.94% | 187.93% | 490.04% | -36.34% | -127.37% | 220.09% | 180947.39% |
| Book Value per Share | -1.58 | -1.73 | -1.25 | 1.20 | 5.83 | 3.47 | -0.86 | 0.76 | 819.93 |
| Total Shareholders' Equity | -6.97M | -7.59M | -8.58M | 7.54M | 44.49M | 28.32M | -7.75M | 9.31M | 16.85B |
| Common Stock | 0 | 0 | 0 | 689 | 810 | 816 | 1.05K | 1.41K | 2.72K |
| Retained Earnings | -7.07M | -7.79M | -8.78M | -14.24M | -28.73M | -54.05M | -110.26M | -134.85M | -163.7M |
| Treasury Stock | 6.73M | 6.88M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -6.83M | -7.08M | -7.08M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANVS Cash Flow Statement
Annovis Bio, Inc. (ANVS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -537.48K | -558.61K | -476.54K | -3.97M | -9.13M | -17.31M | -39.97M | -21.89B | -25.62B |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -3.93% | 14.69% | -733.26% | -129.98% | -89.58% | -130.85% | -54681.29% | -17.01% |
| Net Income | -682.35K | -713.87K | -990.98K | -5.46M | -14.49M | -25.33M | -56.2M | -24.59B | -28.85B |
| Depreciation & Amortization | 0 | 0 | 1.19M | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 48.49K | 82.73K | 8.48K | 1.86M | 4.7M | 9.15M | 4.63M | 3.84B | 1.8B |
| Deferred Taxes | 0 | 0 | -1.19M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 11.58K | 85.41K | 84.43K | 27.02K | 0 | 0 | 11.84M | -1.14B | 1.44B |
| Working Capital Changes | 96.37K | 72.53K | 421.53K | -400.71K | 657.35K | -1.14M | -228.6K | 681.71K | 1.58M |
| Change in Receivables | 0 | 0 | -735.08K | 735.08K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 735.08K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 61.83K | -2.68K | 969.09K | -695.66K | 346.22K | 3.27M | -2.67M | 1.01M | 284.54K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 332.5K | 246.45K | 443.09K | 12.04M | 46.74M | 4.61K | 17.34M | 26.69B | 34.6B |
| Debt Issued (Net) | 0 | 0 | 530K | 12.03M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 9.22K | 1000K | 4.61K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 332.5K | 246.45K | -86.91K | 0 | 95.1K | 0 | 458.38K | 26.67B | 34.57B |
| Net Change in Cash | -204.99K▲ 0% | -312.16K▼ 52.3% | -33.45K▲ 89.3% | 8.07M▲ 24231.0% | 37.61M▲ 365.9% | -17.31M▼ 146.0% | -22.62M▼ 30.7% | 4.8B▲ 21305.0% | 8.98B▲ 87.2% |
| Free Cash Flow | -537.48K▲ 0% | -558.61K▼ 3.9% | -476.54K▲ 14.7% | -3.97M▼ 733.3% | -9.13M▼ 130.0% | -17.31M▼ 89.6% | -39.97M▼ 130.9% | -21.89B▼ 54681.3% | -25.62B▼ 17.0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -3.93% | 14.69% | -733.26% | -129.98% | -89.58% | -130.85% | -54681.29% | -17.01% |
| FCF per Share | -0.12 | -0.13 | -0.07 | -0.63 | -1.20 | -2.12 | -4.43 | -1789.51 | -1246.58 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.78x | 0.48x | 0.73x | 0.63x | 0.68x | 0.71x | 890.37x | 887.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANVS Key Ratios
Annovis Bio, Inc. (ANVS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -72.43% | -55.68% | -69.57% | -546.39% | -3159.09% | -0.34% |
| Interest Coverage | -8119.05x | -10818.18x | - | -0.14x | - | - | - | -14.40x | - |
| FCF Conversion | 0.79x | 0.78x | 0.48x | 0.73x | 0.63x | 0.68x | 0.71x | 890.37x | 887.90x |
ANVS Frequently Asked Questions
Annovis Bio, Inc. (ANVS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Annovis Bio, Inc. (ANVS) grew revenue by 0.0% over the past year. Growth has been modest.
Annovis Bio, Inc. (ANVS) reported a net loss of $28.9M for fiscal year 2025.
Dividend & Returns
Annovis Bio, Inc. (ANVS) has a return on equity (ROE) of -0.3%. Negative ROE indicates the company is unprofitable.
Annovis Bio, Inc. (ANVS) had negative free cash flow of $852.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More ANVS
Annovis Bio, Inc. (ANVS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates